Stephen J Greene1, G Michael Felker2, Anna Giczewska3, Andreas P Kalogeropoulos4, Andrew P Ambrosy5, Hrishikesh Chakraborty6, Adam D DeVore2, Marat Fudim2, Steven E McNulty6, Robert J Mentz2, Muthiah Vaduganathan7, Adrian F Hernandez2, Javed Butler8. 1. Duke Clinical Research Institute, Durham, North Carolina, USA; Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA. Electronic address: stephen.greene@duke.edu. 2. Duke Clinical Research Institute, Durham, North Carolina, USA; Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA. 3. Duke Clinical Research Institute, Durham, North Carolina, USA; Department of Biomedical Engineering, Faculty of Electronics, Telecommunications and Informatics, Gdansk University of Technology, Gdansk, Poland. 4. Division of Cardiology, Stony Brook University, Stony Brook, New York, USA. 5. Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, California, USA; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA. 6. Duke Clinical Research Institute, Durham, North Carolina, USA. 7. Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts, USA. 8. Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Abstract
BACKGROUND:Acute heart failure (HF) patients with renal insufficiency and risk factors for diuretic resistance may be most likely to derive incremental improvement in congestion with the addition of spironolactone. METHODS: The Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure (ATHENA-HF) trial randomized 360 acute HF patients with reduced or preserved ejection fraction tospironolactone100 mg daily or usual care for 96 hours. The current analysis assessed the effects of study therapy within tertiles of baseline estimated glomerular filtration rate (eGFR) and subgroups at heightened risk for diuretic resistance. RESULTS: Across eGFR tertiles, there was no incremental benefit of high-dose spironolactone on any efficacy endpoint, including changes in log N-terminal pro-B-type natriuretic peptide and signs and symptoms of congestion (all P for interaction ≥ 0.06). High-dose spironolactone had no significant effect on N-terminal pro-B-type natriuretic peptide reduction regardless of blood pressure, diabetes mellitus status, and loop diuretic dose (all P for interaction ≥ 0.38). In-hospital changes in serum potassium and creatinine were similar between treatment groups for all GFR tertiles (all P for interaction ≥ 0.18). Rates of inpatient worsening HF, 30-day worsening HF, and 60-day all-cause mortality were numerically higher among patients with lower baseline eGFR, but relative effects of study treatment did not differ with renal function (all P for interaction ≥ 0.27). CONCLUSIONS: High-dose spironolactone did not improve congestion over usual care among patients with acute HF, irrespective of renal function and risk factors for diuretic resistance. In-hospital initiation or continuation of spironolactone was safe during the inpatient stay, even when administered at high doses to patients with moderate renal dysfunction.
RCT Entities:
BACKGROUND:Acute heart failure (HF) patients with renal insufficiency and risk factors for diuretic resistance may be most likely to derive incremental improvement in congestion with the addition of spironolactone. METHODS: The Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure (ATHENA-HF) trial randomized 360 acute HFpatients with reduced or preserved ejection fraction to spironolactone 100 mg daily or usual care for 96 hours. The current analysis assessed the effects of study therapy within tertiles of baseline estimated glomerular filtration rate (eGFR) and subgroups at heightened risk for diuretic resistance. RESULTS: Across eGFR tertiles, there was no incremental benefit of high-dose spironolactone on any efficacy endpoint, including changes in log N-terminal pro-B-type natriuretic peptide and signs and symptoms of congestion (all P for interaction ≥ 0.06). High-dose spironolactone had no significant effect on N-terminal pro-B-type natriuretic peptide reduction regardless of blood pressure, diabetes mellitus status, and loop diuretic dose (all P for interaction ≥ 0.38). In-hospital changes in serum potassium and creatinine were similar between treatment groups for all GFR tertiles (all P for interaction ≥ 0.18). Rates of inpatient worsening HF, 30-day worsening HF, and 60-day all-cause mortality were numerically higher among patients with lower baseline eGFR, but relative effects of study treatment did not differ with renal function (all P for interaction ≥ 0.27). CONCLUSIONS: High-dose spironolactone did not improve congestion over usual care among patients with acute HF, irrespective of renal function and risk factors for diuretic resistance. In-hospital initiation or continuation of spironolactone was safe during the inpatient stay, even when administered at high doses to patients with moderate renal dysfunction.
Authors: Barry M Massie; Christopher M O'Connor; Marco Metra; Piotr Ponikowski; John R Teerlink; Gad Cotter; Beth Davison Weatherley; John G F Cleland; Michael M Givertz; Adriaan Voors; Paul DeLucca; George A Mansoor; Christina M Salerno; Daniel M Bloomfield; Howard C Dittrich Journal: N Engl J Med Date: 2010-10-07 Impact factor: 91.245
Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff Journal: Circulation Date: 2013-06-05 Impact factor: 29.690
Authors: Mori J Krantz; Amrut V Ambardekar; Lisa Kaltenbach; Adrian F Hernandez; Paul A Heidenreich; Gregg C Fonarow Journal: Am J Cardiol Date: 2011-04-12 Impact factor: 2.778
Authors: Andrew P Ambrosy; Peter S Pang; Sadiya Khan; Marvin A Konstam; Gregg C Fonarow; Brian Traver; Aldo P Maggioni; Thomas Cook; Karl Swedberg; John C Burnett; Liliana Grinfeld; James E Udelson; Faiez Zannad; Mihai Gheorghiade Journal: Eur Heart J Date: 2013-01-04 Impact factor: 29.983
Authors: David N Juurlink; Muhammad M Mamdani; Douglas S Lee; Alexander Kopp; Peter C Austin; Andreas Laupacis; Donald A Redelmeier Journal: N Engl J Med Date: 2004-08-05 Impact factor: 91.245
Authors: Lesley H Curtis; Xiaojuan Mi; Laura G Qualls; Devon K Check; Bradley G Hammill; Stephen C Hammill; Paul A Heidenreich; Frederick A Masoudi; Soko Setoguchi; Adrian F Hernandez; Gregg C Fonarow Journal: Am Heart J Date: 2013-04-18 Impact factor: 4.749
Authors: Nancy M Albert; Clyde W Yancy; Li Liang; Xin Zhao; Adrian F Hernandez; Eric D Peterson; Christopher P Cannon; Gregg C Fonarow Journal: JAMA Date: 2009-10-21 Impact factor: 56.272
Authors: Bradley A Bart; Steven R Goldsmith; Kerry L Lee; Michael M Givertz; Christopher M O'Connor; David A Bull; Margaret M Redfield; Anita Deswal; Jean L Rouleau; Martin M LeWinter; Elizabeth O Ofili; Lynne W Stevenson; Marc J Semigran; G Michael Felker; Horng H Chen; Adrian F Hernandez; Kevin J Anstrom; Steven E McNulty; Eric J Velazquez; Jenny C Ibarra; Alice M Mascette; Eugene Braunwald Journal: N Engl J Med Date: 2012-11-06 Impact factor: 91.245
Authors: Filippo Brandimarte; Muthiah Vaduganathan; Gian Francesco Mureddu; Giuseppe Cacciatore; Hani N Sabbah; Gregg C Fonarow; Steven R Goldsmith; Javed Butler; Francesco Fedele; Mihai Gheorghiade Journal: Heart Fail Rev Date: 2013-03 Impact factor: 4.214
Authors: Mohammad Saud Khan; Muhammad Shahzeb Khan; Abdelmoniem Moustafa; Allen S Anderson; Rupal Mehta; Sadiya S Khan Journal: Am J Cardiol Date: 2019-11-19 Impact factor: 2.778
Authors: Brian Kerr; Rebabonye B Pharithi; Matthew Barrett; Carmel Halley; Joe Gallagher; Mark Ledwidge; Kenneth McDonald Journal: Int J Heart Fail Date: 2021-02-25
Authors: Jonathan G Amatruda; Rebecca Scherzer; Veena S Rao; Juan B Ivey-Miranda; Michael G Shlipak; Michelle M Estrella; Jeffrey M Testani Journal: Kidney Med Date: 2022-04-08
Authors: Edmund Ym Chung; Marinella Ruospo; Patrizia Natale; Davide Bolignano; Sankar D Navaneethan; Suetonia C Palmer; Giovanni Fm Strippoli Journal: Cochrane Database Syst Rev Date: 2020-10-27